Introduction
Acute leukemia may present in a variety of extramedullary (EM) tissues with or without bone marrow disease. EM involvement by acute leukemia is a relatively rare, but clinically significant phenomenon that often poses therapeutic dilemmas. Myeloid sarcoma (MS) and leukemia cutis (LC) represent two well-known, extramedullary manifestations. MS (also known as granulocytic sarcoma or chloroma) is a rare extramedullary tumor of immature myeloid cells. It was first described in 1811 1 , and later named 'chloroma' by King 2 in 1853 because of its green color caused by the presence of myeloperoxidase (MPO). 3 Five decades later, the relationship of MS to acute leukemia was identified. 4 The term granulocytic sarcoma was introduced later by Rappaport to describe only tumors of granulocytic origin
however, the term is now often applied to any tumor related to acute leukemia or myelodysplastic syndrome (MDS).
LC is the infiltration of the epidermis, dermis or subcutis by neoplastic leukocytes (leukemia cells) resulting in clinically identifiable cutaneous lesions. LC commonly results in subcutaneous nodules, and can be confusingly referred to as cutaneous granulocytic sarcoma. 6 For the purposes of this article, LC will refer to cutaneous involvement only. LC has been described mostly in acute myeloid leukemia (AML), but also in the accelerated phase of chronic myeloid leukemia (CML), MDS, and rarely in acute lymphocytic leukemias. 7 In this article, we describe an approach and therapeutic strategies for patients with EM manifestations of leukemia by addressing a series of questions commonly raised by the practicing clinician.
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The diagnosis of MS in patients with an established leukemia is relatively straightforward, and should always be included in the differential diagnosis of patients with AML who develop a soft tissue mass. Our practice in these patients is to always attempt to obtain a tissue sample to confirm the diagnosis if the risks of biopsy are reasonable. In general, a fine needle aspiration is usually not adequate for diagnosing a hematological malignancy; however when obtained, immunohistochemistry of the leukemia cells can be valuable. The morphologic appearance of MS on hematoxylineosin can vary according to the degree of myeloid differentiation. MS typically consists of a diffuse and infiltrative population of myeloblasts and granulocytic cell components ( Figure 1 ). The malignant cells are typically large with abundant cytoplasm and large nuclei. Importantly, the neoplastic cell lineage should be consistent with the underlying leukemia. In addition, we routinely send the tissue samples for immunohistochemistry (see below) and when feasible for flow cytometry, fluorescence in-situ hybridization, and molecular analysis although these assays are more difficult to perform on cells in tissue than bone marrow.
Immunohistochemistry is the most practical method for establishing the diagnosis of MS, and can be an easier than flow cytometry, which requires cells to be in suspension. Myelocytic differentiation can be confirmed by Leder stain, 9 which historically has been helpful in establishing the diagnosis in the absence of bone marrow leukemia. Immunohistochemistry can also discriminate between myeloid and nonmyeloid cells with monoclonal antibodies to MPO and lysozyme helpful in this (Figure 2) . 35, 36 CD68-KP1 is the most commonly expressed marker followed by MPO. 35 In the absence of a clinical history of leukemia, a diagnosis of MS can be difficult, and we always make every effort to obtain a tissue diagnosis. MS can often be misdiagnosed, most typically as non-Hodgkin lymphoma (NHL) in up to 46% of patients. 14 This occurs most often with poorly differentiated MS, in which the morphology may resemble large-cell NHL when the cells are MPO negative and weakly stained. 37 Included in the differential diagnosis of MS are other forms of NHL, lymphoblastic leukemia, melanoma, Ewing sarcoma, blastic plasmacytoid dendritic cell neoplasm, and EM hematopoiesis. 38 Similar to patients with a history of leukemia, we also send the tissue samples for immunohistochemistry, flow cytometry, fluorescence in-situ hybridization, and molecular analysis. In addition, once the EM mass is established as leukemia, we perform a bone marrow biopsy, which is sent for identical studies.
Patients with suspected LC should always undergo biopsy unless there is a A variety of chromosomal abnormalities have been reported in patients with AML with EM involvement (Table 1 ). There have been limited associations between cytogenetic abnormalities and MS sites, 40, 41 and further study is required before specific cytogenetic abnormalities can be predict the site of involvement. The t(8;21) translocation is the most common reported cytogenetic abnormality associated with EM involvement, both at presentation and at relapse. 15, 42 In children, it has been associated orbital MS.
40,43
The inv(16) is another cytogenetic abnormality with a higher incidence of EM involvement, particularly in the abdomen. 41 Molecularly, t(8;21) and inv (16) Given the wide variety of sites in which MS develops, imaging can facilitate diagnosis and monitor treatment response. MS often appears as a soft-tissue mass best suited to imaging by computed tomography (CT) ( Figure 3A) . 67 Positron emission tomography (PET) can also be utilized ( Figure 3C ), and is particularly helpful for radiation-therapy (RT) planning 68 and monitoring response to treatment (Figure 4 ). When MS develops in the CNS, magnetic resonance imaging is useful. 69 MS uniformly enhances with gadolinium, which should be administered when there are no contraindications ( Figure   3B poor prognostic factor in the overall evaluation of AML.
The presence of skin involvement has been suggested to be a marker of aggressive disease and poor outcome with shortened survival. 27, 54 However, a more contemporary study of 381 consecutive AML patients did not find that the presence of LC conferred a statistically significant worse response to treatment or shortened survival. 18 Notably, there were trends towards shorter disease remission duration in patients with LC, which did not achieve significance likely due to the low number of patients. 18 We consider LC a marker of aggressive disease that can be difficult to control and patients prone to EM relapses.
Treatment
Treatment strategies for MS are largely dependent upon whether they develop at initial diagnosis or at relapse. LC almost always represents a local manifestation of underlying systemic disease, and therefore should be managed as such. A summary of our treatment approach can be found in Table 2 .
Myeloid sarcoma
Should chemotherapy be initiated for patients with isolated MS without marrow involvement?
Although the optimal timing and treatment of isolated MS is not clear, delayed or inadequately systemically treated isolated MS will almost always progress to AML.
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The median time to the development of AML in this setting ranges from 5 to 12 months. 9, 72, 76 Using reverse transcription-polymerase chain reaction, gene fusions specific for AML, in the bone marrow of patients with isolated MS have been detected suggesting that marrow involvement might occur early in the process prior to clinical detection.
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In our practice, we utilize remission-induction chemotherapy similar to that used for AML. 23, 72, 76, [78] [79] [80] The post-remission chemotherapy has not been adequately studied in isolated MS, and in particular, the role of HCT is not clear. We judge each patient individually and asses multiple prognostic factors including age, co-morbidities, degree of dissemination, cytogenetic-, and molecular-abnormalities when deciding on a postremission strategy. After chemotherapy, we consider RT as a consolidation treatment for isolated MS, particularly since the effective RT dose is low. The radiation site and associated toxicities are important factors in this consideration. In circumstances, which require debulking or rapid symptom relief because of compression of a vital structure, we consider RT or even surgery in certain patients upfront, followed by aggressive chemotherapy; however, there is no evidence that this combined approach is superior to aggressive chemotherapy alone.
Is treatment intensification with HCT after chemotherapy warranted for patients with concurrent MS and marrow involvement?
MS presenting concurrently with marrow involvement always warrants systemic treatment directed at the underlying leukemia. 
Leukemia Cutis
Is chemotherapy indicated in patients with aleukemic LC?
The literature on aleukemic LC is very limited. 93 In our practice, we manage patients with aleukemic LC similarly to isolated MS using intensive chemotherapy.
Is treatment intensification with HCT warranted in patients with LC? When should RT be considered?
Control of cutaneous involvement is essential for long-term disease control because blasts from the skin may reseed the marrow resulting relapse. Therefore, skin-directed therapies like RT can be an important part of treatment. [95] [96] [97] [98] [99] From a radiation perspective, therapy is definitive only in the setting of marrow remission because leukemic cells in the marrow will continue to reseed the skin if they are not eradicated.
In the setting in which there is a negative marrow but persistent LC, our approach is to use total skin electron beam (TSEB) therapy to ensure maximal disease control. 99 By contrast, we treat patients with active marrow disease at the time of RT in a palliative manner, with RT directed at symptomatic lesions only. In such patients, RT provides rapid symptom relief of lesion-associated pain and pruritus. 99 TSEB is not appropriate in this setting unless the patient has diffuse, symptomatic disease. In patients in whom there is a complete response in the skin and marrow following chemotherapy, there is no evidence that RT offers any benefit.
Is toxicity a concern when chemotherapy is administered near the time of radiation?
While generally well tolerated, it is important for both hematologists/oncologists and radiation oncologists to be aware of the development of subacute severe skin toxicity.
Previous cases in the literature describe the development of a severe skin reaction with doxorubicin administered near the time of TSEB. 54,100 Therefore, it has been suggested that high-dose cytarabine should be used in place of anthracyclines when chemotherapy is to be given in conjunction with RT. 54 However, in our recent series, a case of severe radiation recall occurred after administration of clofarabine and cytarabine raising questions about these recommendations. 99 Caution is advised when chemotherapy is being administered shortly after radiation, particularly TSEB.
Should patients with MS or LC be followed differently than other AML patients?
Patients with MS and LC have predisposition to EM relapses. 94 After treatment, we follow patients with MS or LC similar to other AML patients including detailed physical examinations and routine peripheral blood to confirm continued complete remission. We always biopsy any new or suspicious soft tissue or skin abnormality, and if positive for
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What is our current understanding of the pathogenesis of EM?
The mechanisms for EM involvement are not fully understood. In general, homing to specific tissues is intricately controlled by expression of different chemokine receptors and adhesion molecules. Blast neural-cell adhesion molecule (NCAM, CD56) has long been implicated in EM pathogenesis ( Figure 5 ).
14 Supporting this, NCAM blast expression has been associated with a high incidence of MS, 101, 102 and is common in patients with t(8;21). 103 Mechanistically, NCAM is also highly expressed in breast, testicular, ovarian and gut tissue, which could account for EM homing to these sites. 85, 104 In the case of inv (16) Our understanding of EM involvement needs to evolve in parallel with our expanding knowledge of AML. The frequency with which EM disease has distinct genetic or cytogenetic profiles from the marrow will require further study. In the case of abnormal cytogenetics, the concordance between marrow and tissue needs to be established, and if discordant, the abnormalities driving prognosis identified. In the case normal cytogenetics, the mutation status of genes known be prognostically important in AML such as NPM1 and FLT3, as well as other novel mutations, needs to be more rigorously studied in MS, and their prognostic significance and concordance with the marrow better defined. It might also be of interest to study the molecular and cytogenetic concordance as a function of time from marrow involvement. Conceivably, 
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